Arif Khan, MD

Bupropion-Dextromethorphan for Clinically Challenging Apathy

April 2, 2026

This case shows potential benefits of glutamate system–activating medication in addressing clinically challenging apathy in a 44-year-old man with depression.

Wisam Al Jumaili, Nibras Al Gburi, Shailesh Jain, et al

Article

Vilazodone and Psychic and Somatic Anxiety

April 28, 2016

Is the SSRI vilazodone effective for treating generalized anxiety disorder? To comprehensively evaluate the effect of vilazodone across the range of anxiety symptoms associated with the disorder, Khan and...

Arif Khan, Suresh Durgam, Adam Ruth, et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder

April 15, 2011

Arif Khan, Heidi Whalen, Carol R. Reed, et al

ASCP Corner

Is the Problem of a High Placebo Response Unique to Antidepressant Trials?

December 31, 2008

Arif Khan, Amritha Bhat

Original Research

The History and Current State of Antidepressant Clinical Trial Design: A Call to Action for Proof-of-Concept Studies

October 31, 2008

Maurizio Fava, Madhukar H. Trivedi, Michael E. Thase, et al

ASCP Corner

Are Antidepressants Effective? What's a Clinician to Think?

June 30, 2008

Michael E. Thase, J. Craig Nelson, Arif Khan

Original Research

Mortality Risk in Patients With Schizophrenia Participating in Premarketing Atypical Antipsychotic Clinical Trials

December 14, 2007

Arif Khan, Kelly Schwartz, Chelsea Stern, et al

Original Research

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

June 15, 2007

Robert D. McQuade, Ronald N. Marcus, William H. Carson, et al

Original Research

Relapse Prevention of Panic Disorder in Adult Outpatient Responders to Treatment With Venlafaxine Extended Release

January 15, 2007

Arif Khan, Richard Mangano, Evan Tzanis, et al

Original Research

The Effect of a Switch to Ziprasidone in an Adult Population With Autistic Disorder: Chart Review of Naturalistic, Open-Label Treatment

January 1, 2004

Arif Khan, Seth A. Cohen, Brian J. Fitzgerald, et al

Original Research

Weight, Lipids, Glucose, and Behavioral Measures With Ziprasidone Treatment in a Population With Mental Retardation

January 15, 2003

Arif Khan, Seth Cohen, Shirin Khan, et al

Original Research

Weight Gain With Risperidone Among Patients With Mental Retardation: Effect of Calorie Restriction

February 2, 2001

Arif Khan, Seth Cohen, Robert Glazewski, et al

Bupropion-Dextromethorphan for Clinically Challenging Apathy

Vilazodone and Psychic and Somatic Anxiety

A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder

Is the Problem of a High Placebo Response Unique to Antidepressant Trials?

The History and Current State of Antidepressant Clinical Trial Design: A Call to Action for Proof-of-Concept Studies

Are Antidepressants Effective? What's a Clinician to Think?

Mortality Risk in Patients With Schizophrenia Participating in Premarketing Atypical Antipsychotic Clinical Trials

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Relapse Prevention of Panic Disorder in Adult Outpatient Responders to Treatment With Venlafaxine Extended Release

The Effect of a Switch to Ziprasidone in an Adult Population With Autistic Disorder: Chart Review of Naturalistic, Open-Label Treatment

Weight, Lipids, Glucose, and Behavioral Measures With Ziprasidone Treatment in a Population With Mental Retardation

Weight Gain With Risperidone Among Patients With Mental Retardation: Effect of Calorie Restriction

ELSEWHERE:

FOLLOW US:

Arif Khan, MD

Bupropion-Dextromethorphan for Clinically Challenging Apathy

Vilazodone and Psychic and Somatic Anxiety

A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder

Is the Problem of a High Placebo Response Unique to Antidepressant Trials?

The History and Current State of Antidepressant Clinical Trial Design: A Call to Action for Proof-of-Concept Studies

Are Antidepressants Effective? What's a Clinician to Think?

Mortality Risk in Patients With Schizophrenia Participating in Premarketing Atypical Antipsychotic Clinical Trials

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Relapse Prevention of Panic Disorder in Adult Outpatient Responders to Treatment With Venlafaxine Extended Release

The Effect of a Switch to Ziprasidone in an Adult Population With Autistic Disorder: Chart Review of Naturalistic, Open-Label Treatment

Weight, Lipids, Glucose, and Behavioral Measures With Ziprasidone Treatment in a Population With Mental Retardation

Weight Gain With Risperidone Among Patients With Mental Retardation: Effect of Calorie Restriction

Insightful. Evidence-based. Human-centered.

Subscribe to readmore articles

Subscribe to read
more articles